UPDATE: Morgan Stanley Reiterates on CVS/Caremark Following Acquisition of Coram
In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on CVS/Caremark Corporation (NYSE: CVS), but removed the $65.00 price target.
In the report, Morgan Stanley noted, “CVS' $2.1 billion acquisition of Coram, Apria's home infusion business should help solidify CVS' position in the HC continuum and in enhancing its relationships with health systems and ACOs in our view. Importantly, we don't think deal stands in way of supply chain/sourcing partnership.”
CVS/Caremark closed on Wednesday at $66.76.
Latest Ratings for CVS
|Mar 2016||Credit Suisse||Assumes||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.